Education
About Us
Working with TipRanks
Follow Us
Nanobiotix SA (FR:NANO)
:NANO
Earnings Data
Report Date
May 14, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.51Last Year’s EPS
-0.26Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 02, 2025
|% Change Since: -7.50%
|Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong collaborations, especially with JNJ, advancements in clinical trials, and financial strategies to ensure sustainability. Despite financial lowlights such as negative revenue impacts and increased net loss, the strategic developments and pipeline progress suggest a promising future.Company Guidance
In the recent conference call, Nanobiotix provided comprehensive guidance on its financial and operational achievements for the fiscal year 2024, along with future projections. The company highlighted its collaboration with Johnson & Johnson, which involves a $2.6 billion plus royalties agreement, focusing on NBTXR3, now branded as JNJ-1900, targeting lung and head and neck cancers. This collaboration alone could potentially address over 100,000 patients in the U.S. and EU5, translating into a $10 billion market opportunity. Nanobiotix also launched its Curadigm platform, a first-in-class product poised to address multiple therapeutic areas. Financially, the company received a $20 million milestone payment in 2024 related to the NANORAY-312 trial and has extended its cash runway to mid-2026, with plans to explore nondilutive financing options to potentially extend this to 2027. The fiscal year concluded with a net loss increase of 72% to €68.1 million, primarily due to a onetime negative revenue impact from the transfer of study sponsorship to JNJ, which is a noncash item. The company ended 2024 with €49.7 million in cash and cash equivalents, compared to €75.3 million in the previous year.Strong Partnership with Johnson & Johnson
Nanobiotix has made significant progress with its collaboration with JNJ, which includes a $2.6 billion agreement with potential royalties. The collaboration is expanding into different indications such as lung cancer and head and neck cancer, potentially addressing over 100,000 patients and a $10 billion market in the US and EU5.
Progress in Clinical Trials
Multiple clinical trials are advancing well, including the pivotal Phase 3 study NANORAY-312 for head and neck cancer and the Phase 2 CONVERGE study for lung cancer initiated by JNJ. Early-stage trials show promising data in various cancers such as pancreatic, lung, and esophageal cancer.
Financial Strategy and Sustainability
Nanobiotix has extended its cash runway to mid-2026 and is exploring nondilutive financing to extend it further into 2027. The company has also amended its agreement with JNJ, reducing its funding obligations and improving its financial outlook.
Launch of Curadigm Platform
The company launched Curadigm, a next-generation nanotherapeutic platform, expected to impact multiple therapeutic areas and create potential partnerships with biotech and pharma industries.
---
FR:NANO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FR:NANO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 02, 2025 | €3.20 | €3.07 | -4.13% |
| Nov 06, 2024 | €3.91 | €3.87 | -0.97% |
| Sep 18, 2024 | €4.45 | €4.65 | +4.31% |
| May 22, 2024 | €6.51 | €5.70 | -12.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Nanobiotix SA (FR:NANO) report earnings?
Nanobiotix SA (FR:NANO) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
What is Nanobiotix SA (FR:NANO) earnings time?
Nanobiotix SA (FR:NANO) earnings time is at May 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Nanobiotix SA stock?
The P/E ratio of Nanobiotix is N/A.
What is FR:NANO EPS forecast?
FR:NANO EPS forecast for the fiscal quarter 2025 (Q1) is -0.51.
---